Tear Based Neurodegenerative Biomarkers for Alzheimers Disease Screening in Latin America
Bailey, M.; Takyar, A.; Nolasco, M.; Trantow, R.; Sanchez Coronel, D. A.; Diaz, M. M.
Show abstract
Structured AbstractO_ST_ABSBackgroundC_ST_ABSAlzheimers disease (AD) prevalence is rising globally, with low- and middle-income countries (LMICs) facing diagnostic challenges. We investigated the potential for tear-based biomarkers as a non-invasive diagnostic tool for AD. MethodsTear samples were collected from 11 patients with MCI or dementia (neurocognitive disorder, NCD) and 5 age-matched cognitively healthy controls at a public hospital in Lima, Peru. Proteins were analyzed for neurodegenerative biomarkers (amyloid-beta 40/42, total tau, phosphorylated tau181 [pTau181], -synuclein, and neurofilament light). ResultsA custom digital ELISA assay on the NanoMosaic platform revealed significantly elevated levels of total tau (p=0.0023) and pTau181 (p=0.0016) in NCD samples compared to controls. Additionally, the pTau181 to total tau ratio was markedly higher in the NCD group (p = 0.007). ConclusionThese findings suggest that tear-based biomarkers, particularly total tau and pTau181, hold promise as a feasible, non-invasive approach for AD screening and diagnosis in resource-limited settings.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Association of Item-Level Responses to Cognitive Function Index with Tau Pathology and Hippocampal volume in The A4 Study 94%
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 93%
- Self-reported word-finding complaints are associated with cerebrospinal fluid beta-amyloid and atrophy in cognitively normal older adults 93%
Similar papers in this journal
- The Association of Alzheimer’s Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa 96%
- Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer’s disease 96%
- CSF sphingomyelins in Alzheimer’s disease, neurodegeneration, and neuroinflammation 93%
Similar papers in this journal
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 94%
- Identifying Proteomic Prognostic Markers for Alzheimer’s Disease with Survival Machine Learning: the Framingham Heart Study 93%
- Plasma brain-derived p-tau217 outperforms other p-tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden 93%
Similar papers in this journal
- CSF p-tau181 Increases in Patients with Neuronal Intranuclear Inclusion Disease without Amyloid Burden 94%
- CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators 93%
- Susceptibility to postmortem (co)-pathologies in antemortem atrophy-based subtypes of Alzheimer’s disease 93%